Physician profile
Prash Jayaraj
NPI 1487672176
$18,138.97
in general payments reported to CMS, 2019-2025
28 companies · $1,103 in 2025
The $1,103 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,344 · 2020: $1,143 · 2021: $1,825 · 2022: $2,514 · 2023: $2,660 · 2024: $1,550 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,312.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,392.52 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Accolade Sr |
| Acutus Medical, INC. | $4,574.06 | 2019-2022 | |
| Abbott Laboratories | $4,430.91 | 2019-2024 | Gallant, Jot Dx, Cardiomems |
| Medtronic, INC. | $1,582.20 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Tyrx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $551.08 | 2019-2024 | Lifevest |
| Stereotaxis INC | $208.17 | 2019 | |
| Cardiva Medical, INC. | $162.43 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Biotronik INC. | $143.86 | 2019 | |
| Cvrx, INC. | $118.51 | 2022 | |
| Covidien Lp | $112.82 | 2019 | |
| Medtronic Vascular, INC. | $97.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $90.62 | 2023-2025 | Breztri, Farxiga |
| Pfizer INC. | $89.36 | 2023-2025 | |
| Biosense Webster, INC. | $86.17 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $67.19 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.81 | 2022-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $62.02 | 2019-2022 | |
| Edwards Lifesciences Corporation | $48.91 | 2024 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $48.13 | 2023 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $47.77 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $32.59 | 2021-2022 | |
| Altathera Pharmaceuticals LLC | $25.00 | 2024 | Sotalol Hydrochloride |
| Biom'Up France Sas | $21.61 | 2020 | |
| Philips North America LLC | $20.45 | 2022 | |
| Amgen INC. | $18.17 | 2019 | |
| Chiesi USA, INC. | $16.01 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.92 | 2021 | |
| Bardy Diagnostics, INC. | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prash Jayaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.